Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Cash flows from operating activities:
Net loss	$ (5,865,000)	$ (3,099,000)
Adjustments to reconcile net loss to net cash provided by operating activities, net of effect of acquisitions:
Depreciation	450,000	774,000
Amortization of capitalized software development costs	1,160,000	2,113,000
Amortization of intangible assets	937,000	1,161,000
Amortization of other deferred costs	415,000	341,000
Valuation adjustment	126,000	95,000
Impairment of long-lived assets	3,681,000
Loss on exit of operating lease	1,034,000
Loss (gain) on disposal of fixed assets	7,000	(16,000)
Share-based compensation expense	629,000	1,109,000
Provision for accounts receivable	13,000	234,000
Changes in assets and liabilities, net of assets acquired:
Accounts and contract receivables	(640,000)	1,498,000
Other assets	466,000	(696,000)
Accounts payable	859,000	(695,000)
Accrued expenses	129,000	(117,000)
Deferred revenues	(2,004,000)	(671,000)
Net cash provided by operating activities	1,397,000	2,031,000
Cash flows from investing activities:
Purchases of property and equipment	(21,000)	(49,000)
Proceeds from sales of property and equipment	21,000	20,000
Capitalization of software development costs	(3,003,000)	(1,836,000)
Net cash used in investing activities	(3,003,000)	(1,865,000)
Cash flows from financing activities:
Principal repayments on term loans	(597,000)	(1,112,000)
Principal payments on capital lease obligations		(91,000)
Payments related to settlement of employee shared-based awards	(62,000)	(42,000)
Proceeds from exercise of stock options and stock purchase plan	44,000	45,000
Payment of deferred financing costs	(23,000)
Net cash used in financing activities	(638,000)	(1,200,000)
Net decrease in cash and cash equivalents	(2,244,000)	(1,034,000)
Cash and cash equivalents at beginning of year	4,620,000	5,654,000
Cash and cash equivalents at end of year	2,376,000	4,620,000
Supplemental cash flow disclosures:
Interest paid	417,000	418,000
Income taxes paid	11,000	$ 8,000
Supplemental disclosure of non-cash financing activities:
Conversion of Series A Preferred Stock to common shares	$ 164,000
Conversion of Series A Preferred Stock to common shares (in shares)	54,531
Modification of royalty liability associated with the acquisition of Clinical Analytics	$ 1,644,000